These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 25976165)
1. Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells. D'Alimonte I; Nargi E; Zuccarini M; Lanuti P; Di Iorio P; Giuliani P; Ricci-Vitiani L; Pallini R; Caciagli F; Ciccarelli R Purinergic Signal; 2015 Sep; 11(3):331-46. PubMed ID: 25976165 [TBL] [Abstract][Full Text] [Related]
2. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy. Daniele S; Zappelli E; Natali L; Martini C; Trincavelli ML Cell Death Dis; 2014 Nov; 5(11):e1539. PubMed ID: 25429616 [TBL] [Abstract][Full Text] [Related]
3. Upregulation of Epithelial-To-Mesenchymal Transition Markers and P2X7 Receptors Is Associated to Increased Invasiveness Caused by P2X7 Receptor Stimulation in Human Glioblastoma Stem Cells. Ziberi S; Zuccarini M; Carluccio M; Giuliani P; Ricci-Vitiani L; Pallini R; Caciagli F; Di Iorio P; Ciccarelli R Cells; 2019 Dec; 9(1):. PubMed ID: 31905754 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
5. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells. Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773 [TBL] [Abstract][Full Text] [Related]
6. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). Choi J; Lee JH; Koh I; Shim JK; Park J; Jeon JY; Yun M; Kim SH; Yook JI; Kim EH; Chang JH; Kim SH; Huh YM; Lee SJ; Pollak M; Kim P; Kang SG; Cheong JH Oncotarget; 2016 Oct; 7(40):65643-65659. PubMed ID: 27582539 [TBL] [Abstract][Full Text] [Related]
7. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862 [TBL] [Abstract][Full Text] [Related]
8. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059 [TBL] [Abstract][Full Text] [Related]
9. Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells. Lai IC; Shih PH; Yao CJ; Yeh CT; Wang-Peng J; Lui TN; Chuang SE; Hu TS; Lai TY; Lai GM PLoS One; 2015; 10(3):e0114830. PubMed ID: 25763821 [TBL] [Abstract][Full Text] [Related]
10. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo. Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379 [TBL] [Abstract][Full Text] [Related]
12. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Auffinger B; Tobias AL; Han Y; Lee G; Guo D; Dey M; Lesniak MS; Ahmed AU Cell Death Differ; 2014 Jul; 21(7):1119-31. PubMed ID: 24608791 [TBL] [Abstract][Full Text] [Related]
13. Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme. Bielecka-Wajdman AM; Lesiak M; Ludyga T; Sieroń A; Obuchowicz E Cancer Chemother Pharmacol; 2017 Jun; 79(6):1249-1256. PubMed ID: 28500556 [TBL] [Abstract][Full Text] [Related]
14. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. Zhang S; Wan Y; Pan T; Gu X; Qian C; Sun G; Sun L; Xiang Y; Wang Z; Shi L J Mol Neurosci; 2012 Jun; 47(2):346-56. PubMed ID: 22528454 [TBL] [Abstract][Full Text] [Related]
16. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide. Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977 [TBL] [Abstract][Full Text] [Related]
18. P2X7 receptors at adult neural progenitor cells of the mouse subventricular zone. Messemer N; Kunert C; Grohmann M; Sobottka H; Nieber K; Zimmermann H; Franke H; Nörenberg W; Straub I; Schaefer M; Riedel T; Illes P; Rubini P Neuropharmacology; 2013 Oct; 73():122-37. PubMed ID: 23727220 [TBL] [Abstract][Full Text] [Related]
19. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
20. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]